.Charles Baum, M.D., Ph.D., who oversaw Mirati Rehabs' $ 5.8 billion sale to Bristol Myers Squibb last year, is taking the reins of young biotech Terremoto Biosciences.Baum's "significant adventure in medicine development, and tested track record ahead of time high-impact medications, will certainly be instrumental," outgoing chief executive officer Peter Thompson, M.D., stated in a July 25 release. Thompson is going to retain his chair as board chairperson..Baum, a trained physician-scientist, was the creator, head of state and chief executive officer of oncology-focused Mirati. Prior to that, he assisted create cancer drugs at Pfizer and also Schering-Plough..
Charles Baum, M.D., Ph.D.(( Mirati)).Now, Baum will definitely act as chief executive officer at Terremoto, a provider cultivating tiny particles to target disease-causing proteins-- like those found in harmful cyst cells-- making use of covalent bonds. Existing treatments that make use of covalent connections mainly target the amino acid cysteine. However, of the 20 amino acids that compose healthy proteins, cysteine is the least common. Terremoto is as an alternative targeting among the important amino acids, lysine, which is actually found in almost all healthy proteins.By targeting amino acid lysine and other amino acids, Terremoto expects to alleviate formerly undruggable conditions as well as produce first-in-class medicines..The biotech, based in South San Francisco, raised $75 million in series A financing in 2022. A little bit of much more than a year eventually, the biotech greater than doubled that variety in a $175 million series B.